The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - BMS, Amgen
Genomic characteristics, clinical profiling, and outcomes of advanced pancreatic ductal adenocarcinoma (PDAC) with MTAP-deletion (MTAP-del): Analyses from a multimodal real-world dataset.
 
Micaela Tatman
Employment - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Daiane Hemerich Brennan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Chunan Liu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Rachel Webster
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shubham Pant
Stock and Other Ownership Interests - Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Alligator Bioscience; Amgen; Aptitude Health; Arcus Biosciences; Astellas Pharma; AstraZeneca; Basilea; Baxter; BioLineRX; Boehringer Ingelheim; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Novocure; Paraxel; PEGASCY; Prime Oncology; QED Therapeutics; Revolution Medicines; Roche; Sanofi/Aventis; SERVIER; Taiho / Keylates; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Tyler Simpson
No Relationships to Disclose
 
Wen-Chi Chou
Employment - Bristol-Myers Squibb
 
Ruslan Novosiadly
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Lilly
 
Aparna Chhibber
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - DOSAGE REGIMEN FOR ADMINISTRATION OF BELZUTIFAN Publication number: 20240327929 Abstract: The present disclosure provides a method of treating cancer or von Hippel-Lindau (VHL) disease with a safe and effective therapeutic dose of belzutifan in a patient
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Gonzalo Lopez
Employment - bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Ming Lei
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb